In an industry where many manufacturers compete on price, certification, and capacity, process innovation is a meaningful differentiator.
For an emerging Indian pharmaceutical company, holding a granted manufacturing-process patent signals the capability to develop and protect proprietary pharmaceutical knowledge.
What process innovation means
Pharmaceutical process innovation covers activities ranging from novel formulation techniques and modified delivery systems to manufacturing-method improvements that enhance reproducibility, efficiency, or the ability to produce technically challenging formulations.
Unlike product patents, process patents protect the method by which a product is made. In generic pharmaceutical manufacturing, process patents can create meaningful differentiation through a legally protected and technically developed manufacturing approach.
Swift's Single Pot DRC Technology
Swift Life Sciences holds Indian Patent IN551347 covering Single Pot DRC Technology, a proprietary process innovation developed through its Center for Innovations.
The patent reflects Swift's direction toward becoming a research-led pharmaceutical enterprise alongside its established manufacturing capabilities. Details concerning specific applications and commercial availability can be discussed with verified pharmaceutical business partners.
DCGI-approved sustained-release suspension
Swift has received approval from the Central Drugs Controller General of India for a Dextromethorphan Hydrobromide and Chlorpheniramine Maleate sustained-release suspension.
The formulation combines an antitussive with an antihistamine in a sustained-release liquid format. The approval reflects internal formulation-development capability and experience navigating regulatory requirements for an independently developed product.
An expanding innovation pipeline
Beyond the approved product, Swift has additional formulations under regulatory review. As regulatory clearances are received, selected products may be added to the company's commercial portfolio.
What this means for manufacturing partners
A facility that actively develops formulations, holds granted patents, and obtains regulatory approvals for internally developed products demonstrates scientific capability, regulatory navigation experience, and long-term investment in differentiated manufacturing.
Explore Swift's broader innovation direction, facility capability, and product portfolio.
Explore a research-led partnership
For verified discussions concerning partnership, licensing, product development, or manufacturing, submit a business enquiry.